New York, NY -- (SBWIRE) -- 01/21/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Progenics Pharmaceuticals, Inc (NASDAQ:PGNX), Exelixis, Inc (NASDAQ:EXEL), Globalstar, Inc (OTCMKTS:GSAT), Avanir Pharmaceuticals Inc (NASDAQ:AVNR)
Progenics Pharmaceuticals, Inc (NASDAQ:PGNX) showed a volume of 1.63 million shares by the end of last trade whereas the average volume of the stock remained 1.06 million shares. The stock opened the session at $6.90 but then moved to $7.04. At that price, the stock showed a positive performance of 2.18%. Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers.
Will PGNX Continue To Move Higher? Find Out Here
Exelixis, Inc (NASDAQ:EXEL) opened the session at $8.14 and closed the session at $8.08. The stock showed a negative performance of -0.86% in previous trading session. Traded with volume of 1.63 million shares in the prior session and the average volume of the stock remained 2.20 million shares. Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer.
Has EXEL Found The Bottom And Ready To Gain Momentum? Find Out Here
Globalstar, Inc (OTCMKTS:GSAT) opened the session at $1.87 and closed the session at $1.85. Traded with volume of 1.62 million shares in the prior session and the average volume of the stock remained 4.49 million shares. The beta of the stock remained 3.07. Globalstar, Inc. (Globalstar) is a provider of mobile voice and data communications services globally via satellite. Globalstar’s satellite communications business, by providing critical mobile communications to the Company's subscribers, serves principally recreation and personal; government; public safety and disaster relief; oil and gas; maritime and fishing.
Is GSAT a Solid Investment at These Levels? Read This Report For Details
Avanir Pharmaceuticals Inc (NASDAQ:AVNR) the stock advanced 0.76% and finished the session at $3.83. Traded with volume of 1.62 million shares in the prior session and the average volume of the stock remained 3.25 million shares. The beta of the stock remained 1.36. AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system.
Will AVNR Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)